Peptide Decoding
News

Trevogrumab Cut Muscle Loss on Semaglutide. Nobody Measured Strength

By Allison Thorne · Editorial standards
Published November 16, 2026
A body-composition scan of a thigh on a backlit panel, with a single unlabeled glass vial standing in front of it

Semaglutide alone cost people 6.6% of their muscle and other lean tissue over 26 weeks. Adding a second drug, trevogrumab, gave back 3.1 percentage points of that, in results published in The Lancet on November 11, 2026.1

Whether holding onto that tissue changes anything a person can do is not a question the trial set out to answer. The authors say as much in their own conclusion. What the trial measured and what people will assume it measured are two different things.

What did the trial actually test?

The trial ran at 60 US sites and enrolled 975 people between June 21, 2024 and April 14, 2025, with entry requiring a BMI of 30 or above and an age between 18 and 80. Mean age was 49.0 years and mean BMI was 36.7. Of the 975, 627 were women and 348 were men.1

The trial came in two parts with different drugs at different doses, and most coverage has treated them as one. Part A put 605 people on semaglutide titrated to 2.4 mg weekly for 26 weeks, the dose sold as Wegovy rather than the lower one sold as Ozempic, then split them four ways: placebo, trevogrumab 200 mg, trevogrumab 400 mg, or trevogrumab 400 mg combined with garetosmab 10 mg/kg. Trevogrumab was injected weekly under the skin. Garetosmab was infused by vein every four weeks.1

Trevogrumab's target is GDF8, the protein better known as myostatin. GDF8 limits how much muscle a body builds, and trevogrumab blocks it. Garetosmab blocks activin A, a second brake on the same system, so the combination arm was releasing both brakes at once. Both drugs are Regeneron antibodies and Regeneron funded the trial, registered as NCT06299098.1

How much muscle do you lose on semaglutide?

Muscle and other lean tissue fell 6.6% by week 26 in the group taking semaglutide with a placebo, on a confidence interval running from 5.7% to 7.4%, while fat mass in the same group fell 15.6% and total body weight fell 10.6%.1

So roughly a third of what came off was lean tissue. The share is consistent with what the older trials found, and our guide on what happens to muscle, skin, hair and bone after major weight loss covers the earlier numbers. The figure is also the reason this class of drug exists: a third of a 10% weight loss is a lot of tissue to give up, and nobody set out to lose it.

How much muscle did trevogrumab save?

Every trevogrumab dose in Part A saved muscle against placebo, and the margins were not small.

Part A, week 26 Lean mass, difference from semaglutide alone Fat mass Body weight
Semaglutide + placebo 6.6% lost (CI 5.7 to 7.4) 15.6% lost 10.6% lost
+ trevogrumab 200 mg 3.1 points better (CI 1.9 to 4.3) no significant difference no significant difference
+ trevogrumab 400 mg 2.7 points better (CI 1.5 to 4.0) 3.4 points more lost no significant difference
+ trevogrumab 400 mg and garetosmab 4.5 points better (CI 3.1 to 5.9) 11.7 points more lost 2.7 points more lost

The lean mass column shows a clear pattern. The other two columns show something else: only one trevogrumab dose moved fat loss, and no trevogrumab dose on its own moved the scale at all.1

Why did the lower dose beat the higher one?

The lower dose beat the higher one, preserving 3.1 points of lean mass against 2.7 for double the dose.1 Twice the drug produced slightly less of the effect the drug exists to produce.

The confidence intervals overlap heavily, so the two doses are not separated by this trial and the ordering could be noise. The abstract offers no explanation, and the full text sits behind a paywall we have not opened. The higher dose did do one thing the lower dose did not, shifting fat loss by 3.4 points more than placebo.1 The two doses may therefore be doing different jobs, one holding tissue and one moving fat, and a trial of this size cannot settle which. Anyone picking a dose off this paper is picking between two overlapping estimates.

What does 3.1 points look like on a person?

Percentages hide what the difference would look like on a person. The paper reports lean mass only as a percentage change. Pounds have to come from elsewhere.

Regeneron's own September 2025 release, covering the same Part A arms, put the lean mass loss at 3.3 kg on semaglutide alone against 1.5 kg with trevogrumab 200 mg.2 Converted, those are about 7.3 pounds of lean tissue against about 3.3. The conversion is this page's arithmetic on the company's figures. In the same release, lean tissue made up 33.0% of the weight lost on semaglutide alone and 16.8% with trevogrumab.2

Treat those as company numbers. They are a press release, not the peer-reviewed paper, and the release puts semaglutide-alone lean mass loss at 6.5% where the paper reports 6.6%.

Does preserving lean mass mean preserving strength?

No study has shown that preserving lean mass preserves strength. The authors are the ones saying so. Their conclusion calls for further study to understand whether better body composition during weight loss might preserve physical function and overall metabolic health.1

Lean mass on a DXA scan is tissue on a scan. Strength, walking speed, stair climbing, grip and the ability to get out of a chair are different measurements, and this trial did not report them. The trial did run an exploratory MRI substudy of thigh muscle volume, and participants were stratified by whether they took part in it. Volume is still not function.1

Readers have met this gap before on this site. The retatrutide registrational trial never measured body composition at all. That was a different hole in a different paper, and the pattern of a weight-loss trial leaving the muscle question out is becoming familiar.

What did adding garetosmab do?

Adding garetosmab worked better than blocking one brake alone. The triplet preserved 4.5 points of lean mass, lost 11.7 points more fat than semaglutide alone, and was the only arm in the trial that moved total body weight significantly, by 2.7 points.1

The fat figure is the largest number in the trial. Semaglutide with placebo cut fat mass 15.6%, and the triplet cut it 11.7 points further on top of that.1 No trevogrumab dose on its own came close: 400 mg managed 3.4 points more and 200 mg managed none that reached significance.1 Blocking activin A as well as GDF8 did not simply protect muscle, it changed what the weight loss was made of.

On every efficacy measure COURAGE reported, the triplet came first. It is also the arm the authors declined to endorse, and the next section is why.

Why is the best arm the one nobody wants?

Efficacy and safety ran in opposite directions here, so the best arm was also the most dangerous one. Safety ran hard in the wrong direction. In the garetosmab group, 14 of 149 people had a serious adverse event, or 9%, and treatment discontinuations reached 48 of 149, or 32%. Muscle spasms affected 61 of 149, 41%, against 23 of 299 on trevogrumab alone and 7 of 151 on semaglutide with placebo.1

Two people died during the trial. Both were in the garetosmab group. The authors state that a causal association between treatment and those events was not identified.1 Not identified is not the same as ruled out, and it is also not evidence of harm. Two deaths among 149 people is a number no phase 2 trial can interpret on its own, and a larger trial would be needed to say anything about rate. The discontinuation figure needs no statistician. A third of the people assigned to that combination stopped taking it, and stopping is a verdict participants reached themselves.

The authors' own summary splits the two findings cleanly. Trevogrumab alone is the proof of concept. The combination improved body composition and weight loss and did not have favorable safety and tolerability.1

What did the second part of the trial find?

Part B tested much smaller doses for twice as long, and one of the two failed outright. It ran 376 people on semaglutide for 52 weeks, randomized to placebo, trevogrumab 25 mg or trevogrumab 75 mg.1

Lean mass fell 7.3% on semaglutide with placebo over those 52 weeks. The 75 mg dose preserved 3.1 of those points, on a confidence interval from 1.3 to 4.9. The 25 mg dose came in at 1.5 points, with an interval running from minus 0.3 to 3.3.1

An interval crossing zero means the trial did not establish that 25 mg does anything on its primary endpoint. No Part B group differed significantly from placebo on fat mass or on body weight.1

Does Regeneron's release match the paper?

The release and the paper agree on most of it and part ways on the 25 mg arm. Regeneron's October 1, 2026 release described the lower-dose portion as showing 29.9% lean mass preservation at 25 mg and 50.7% at 75 mg, against a placebo group losing 6.7%.3

Those are absolute changes and ratios. The paper's pre-specified primary endpoint is an estimated treatment difference against placebo, and for 25 mg that difference has a confidence interval including zero at week 52.1 The figures are not strictly contradictory, because they are different measures and the release does not name its timepoint. The practical effect is that a reader of the release comes away thinking 25 mg preserved a third of the lean mass, and a reader of the paper comes away unable to say it preserved any.

Where a company document and a peer-reviewed paper describe the same arm differently, the paper's pre-specified endpoint is the stronger of the two.

Can you buy trevogrumab?

Two sellers list it, more than anyone might expect for an antibody no regulator has approved. Our price capture read on November 7, 2026 found trevogrumab carried by two vendors, starting at $194.95.4 Neither of them is Regeneron, and Regeneron has approved and sold it nowhere. Our trevogrumab and GDF-8 pages carry the status and the current listings.

The arithmetic on those listings is the interesting part. Trevogrumab is a monoclonal antibody, a full-size protein grown in cell culture, and the trial dosed it at 200 mg or 400 mg every week by injection.1 Garetosmab was infused at 10 mg/kg. For a 200-pound person that comes to roughly 900 mg a month.1 A research-labeled vial priced near $195 is not plausibly carrying hundreds of milligrams of a monoclonal antibody, and no peptide synthesizer makes one.

We could not retrieve a Finnrick record for trevogrumab, so no independent lab result we can point to exists for anything sold under that name. That is an absence of testing and not evidence about the contents.

The usual checks still apply, with one difference that matters here. A per-lot certificate with the lot number on the vial, a seller on /vendors with no open FDA letter, and a test of the first vial are the same steps as always. For an antibody the test carries more weight than usual, because a purity number from a peptide assay says nothing about whether the contents are an antibody at all.

How does trevogrumab compare with bimagrumab and apitegromab?

Bimagrumab and apitegromab have both reported phase 2 results, and COURAGE cites them. Bimagrumab was tested with semaglutide and published in Nature Medicine in 2026. Apitegromab was tested for lean mass preservation during tirzepatide-induced weight loss and published in the same journal the same year.1

We have not read either paper at source, so this page makes no comparison of effect sizes. Our bimagrumab and apitegromab pages cover what each one is, and anyone choosing between the three on published evidence needs all three papers rather than three press releases. For what the exercise and protein literature says about the same problem without a drug, see lifting and muscle on a GLP-1.

What is known and what is not?

What is known fills a short list, and what is not known fills a longer one, so the two belong apart.

Established by the trial: lean mass, fat mass and body weight changes for every arm in both parts; serious adverse events, discontinuations and muscle spasms by group; two deaths with no causal association identified; the funder, the registration and the enrollment window.1

Not established:

  • Whether any of it protects strength. No grip, gait speed, chair rise or strength outcome appears in the abstract, and the authors ask for further study on exactly this.1
  • What happened after semaglutide stopped. Part A continued another 26 weeks with trevogrumab 400 mg or placebo once semaglutide was withdrawn, and the abstract reports nothing from that period.1
  • What the MRI substudy of thigh muscle volume found. Participants were stratified by whether they joined it, and no result is given.1
  • The figures in pounds. The paper reports percentages only, so the pounds on this page come from a company release.2
  • Whether the two Part A doses differ at all, since their intervals overlap heavily.1
  • What is in a vial sold as trevogrumab, with no testing record retrievable.

What happens next?

COURAGE is listed as active and not recruiting, so the remaining data is already collected.1 Part A included a semaglutide withdrawal period in which participants received trevogrumab 400 mg or placebo for a further 26 weeks, and the abstract reports no results from it.1 Those results would answer a question this page cannot: what happens to the preserved tissue after the weight-loss drug stops.

Regeneron has not announced a phase 3 program for trevogrumab in obesity, and nothing in the paper sets a date. The compound sits on this site as investigational, and the status line on its page moves when a filing or a trial registration appears, not when a release does.

Common questions

Does trevogrumab stop muscle loss on semaglutide?

Trevogrumab cut the loss by 3.1 percentage points, not to zero. In Part A of COURAGE, lean mass fell 6.6% on semaglutide with placebo over 26 weeks.

How much muscle do you lose on semaglutide?

Muscle and other lean tissue fell 6.6% over 26 weeks on semaglutide in the COURAGE placebo group, alongside a 10.6% fall in total body weight, so lean tissue was roughly a third of what came off.

Does keeping lean mass mean keeping strength?

Unknown, and The Lancet paper says so in its own conclusion. It calls for further study on whether better body composition during weight loss preserves physical function, and the trial reported no strength, walking or grip measurements.

Which trevogrumab dose worked best?

Trevogrumab 200 mg preserved the most lean mass in Part A, at 3.1 points against 2.7 points for 400 mg. The confidence intervals overlap, so the trial does not separate the two doses.

Did the lowest dose work?

No, and Part B's 25 mg arm produced a treatment difference of only 1.5 points, on a confidence interval from minus 0.3 to 3.3. The interval includes zero, so its primary endpoint was not met.

What did garetosmab add?

Added to trevogrumab 400 mg, garetosmab 10 mg/kg preserved 4.5 points of lean mass, drove 11.7 points more fat loss, and produced the only significant body weight difference in the trial at 2.7 points.

Was the garetosmab combination safe?

No, with serious adverse events reaching 9% and discontinuations 32% in that group. Muscle spasms affected 41%, and the authors write that the combination did not have favorable safety and tolerability.

Did anyone die in the COURAGE trial?

Two people died, both in the group receiving trevogrumab 400 mg with garetosmab. The authors state that a causal association between treatment and those events was not identified.

How many people were in the trial?

975 people enrolled in the trial, with 605 in Part A and 376 in Part B. The garetosmab group held 149 people and the Part A placebo group held 151.

How long did the trial run?

The trial ran 26 weeks in Part A, with a further 26-week semaglutide withdrawal period, and 52 weeks in Part B. Enrollment closed in April 2025.

Who paid for the trial?

Regeneron Pharmaceuticals paid for the trial and makes both drugs. The paper's corresponding author lists a Regeneron affiliation.

Can you buy trevogrumab?

Not as a medicine, because trevogrumab is an investigational Regeneron antibody that no regulator has approved. Two gray-market sellers listed it in our November 7, 2026 price capture, starting at $194.95, and neither is Regeneron.

Is trevogrumab a peptide?

No, trevogrumab is a monoclonal antibody against GDF8 and a far larger molecule than the synthesized chains most of this site covers. The size is why it is injected in hundreds of milligrams.

What is GDF8?

GDF8 is myostatin, a protein the body uses to limit muscle growth. Blocking it releases that limit, and our GDF-8 page covers the protein and the compounds aimed at it.

How does this compare with bimagrumab or apitegromab?

Bimagrumab and apitegromab have both published phase 2 results in Nature Medicine in 2026, and COURAGE cites them. This page has not read either paper at source and makes no comparison of effect sizes.

When was the COURAGE trial published?

The Lancet published it online on November 11, 2026, as a two-part phase 2 trial registered under NCT06299098.

Sources

  1. Mosenzon O, Rosenstock J, Raya JG, Grimsby JS, Calle RA, Cannon K, et al. Trevogrumab (anti-GDF8) with or without garetosmab (anti-activin A) for prevention of muscle loss during semaglutide-induced weight reduction in people with obesity (COURAGE): a two-part, phase 2, double-blind, placebo-controlled, randomised trial. The Lancet, online first, November 11, 2026. ClinicalTrials.gov NCT06299098. Funded by Regeneron Pharmaceuticals.
    Abstract read at source, full text not retrieved. Every figure on this page comes from the publicly visible abstract. The full text and the 8.89 MB supplementary appendix sit behind a paywall and were not opened, so per-arm weight in pounds, the semaglutide withdrawal period results, the MRI substudy results and all function measurements are unavailable to this page. ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩
  2. Regeneron Pharmaceuticals. Results from Phase 2 COURAGE Trial Demonstrating Potential to Improve Quality of GLP-1 receptor agonist-induced Weight Loss by Preserving Lean Mass, Presented at EASD. September 17, 2025.
    Read at source. A company document, not independent confirmation. Used only for the kilogram figures and the share-of-weight-loss figures, neither of which the paper's abstract gives. This release reports semaglutide-alone lean mass loss as 6.5% where the paper reports 6.6%. The conversion to pounds is this page's arithmetic. ↩ ↩ ↩
  3. Regeneron Pharmaceuticals. Phase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During GLP-1 Receptor Agonist-induced Weight Loss. October 1, 2026.
    Read at source. A company document, not independent confirmation. Cited for how it presents the lower-dose arms, including the 29.9% and 50.7% preservation figures and a placebo group losing 6.7%. The release does not name the timepoint for those figures and does not name garetosmab. ↩
  4. Peptide Decoding. "Trevogrumab." Compound page, status and listings read November 13, 2026. https://peptidedecoding.com/peptides/trevogrumab.
    Read at source (this site). Source of the vendor count and the starting price, from the November 7, 2026 price capture. The lean mass preservation percentages currently on that page come from Regeneron interim and EASD releases and do not match the published paper; see the build notes. ↩

Citing this page: Peptide Decoding. Trevogrumab Cut Muscle Loss on Semaglutide. Nobody Measured Strength. Figures from the COURAGE abstract in The Lancet, published November 11, 2026, and two Regeneron releases dated September 17, 2025 and October 1, 2026. Reviewed November 13, 2026. https://peptidedecoding.com/news/trevogrumab-courage-lancet